12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ficlatuzumab: Additional Phase II data

Additional data from 188 patients with previously untreated NSCLC in the Phase II portion of an open-label, Asian Phase Ib/II trial showed that first-line treatment with ficlatuzumab plus gefitinib missed the secondary endpoint of median PFS vs. gefitinib alone (5.6 vs. 4.7 months, p=0.4664). Aveo said that preliminary OS data showed an OS hazard ratio of 0.84 favoring ficlatuzumab plus gefitinib vs. gefitinib alone (p=0.4926). OS data are not fully mature, with only 32% of events recorded in the ficlatuzumab plus gefitinib arm and 37% in the gefitinib alone arm. Aveo also said that in a subgroup of patients with high levels of stroma HGF (n=17),...

Read the full 506 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >